Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)

NCT02484482 | Completed Phase 1

• 1 other identifier: 148FDI15009
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose this study investigate the effect of food on the pharmacokinetics/pharmacodynamics and safety of CKD-519

Conditions

Dyslipidemia

Outcome Measures

Primary Outcomes (7)

• Cmax of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

• Area under the plasma drug concentration-time curve(AUC0-last) of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

• AUC0-∞ of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

• Tmax of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

• T1/2 of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

• CL/F(Clearance/Bioavailability) of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

• Vd/F of CKD-519

  0(predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

Secondary Outcomes (1)

• Inhibition of CETP(Cholesteryl ester transfer protein) Activity

  0(predose), 1, 2, 4, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168

Study Arms (6)

Group 1

EXPERIMENTAL

CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group. Fasting→Standard Meal→High Fat Meal

Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Group 2

EXPERIMENTAL

CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group. Standard Meal→High Fat Meal→Fasting

Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Group 3

EXPERIMENTAL

CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group. High Fat Meal→Fasting→Standard Meal

Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Group 4

EXPERIMENTAL

CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group. Fasting→High Fat Meal→Standard Meal

Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Group 5

EXPERIMENTAL

CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group. Standard Meal→Fasting→High Fat Meal

Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Group 6

EXPERIMENTAL

CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group. High Fat Meal→Standard Meal→Fasting

Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

Interventions

CKD-519 200mg / Fasting, Standard Meal, High Fat Meal DRUG

Group 1; Group 2; Group 3; Group 4; Group 5; Group 6

Eligibility Criteria

• Age: 19 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Between 19 aged and 55 aged in healthy adult
• Body weight more than 55kg in male, 50kg in female
• Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)
• If female, must include more than one among the items
• The menopause(there is no natural menses for at least 2 years)
• Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition)
• If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms and do not sperm donation until two months during clinical trials and after the final dosage of investigational products
• Those who fully understand about this clinical trials after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent

You may not qualify if:

• Have clinically significant disease that hepatobiliary system(severe hepatic impairment, etc.), kidney(severe renal impairment, etc.), nervous system, immune system, respiratory system, endocrine system, haemato-oncology disease, cardiovascular system(heart failure, etc.) or mental illness, or a history of mental disease.
• Have a gastrointestinal disease history that can effect drug absorption(Crohn's disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)
• Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of drugs or additives.
• An impossible one who participates in clinical trial including screening tests (medical history taking, BP, 12-lead ECG, physical examination, blood\&urine laboratory test result) before 28 days the taking investigational products.
• Defined by the following laboratory parameters
• AST(Aspartate aminotransferase), ALT(Alanine aminotransferase)\>1.25\* upper limit of normal range
• Total bilirubin\>1.5\* upper limit of normal range
• CPK(Creatine phosphokinase)\>1.5\* upper limit of normal range
• eGFR(Estimated Glomerular Filtration Rate, using by MDRD(Modification of Diet in Renal Disease) method)\<60 mL/min/1.73m2
• Sitting SBP(Systolic Blood Pressure )\>150 mmHg or \<90 mmHg, sitting DBP(Diastolic Blood Pressure )\>100 mmHg or 50 mmHg , after 5 minutes break.
• Drug abuse or have a history of drug abuse shows a positive for urine drug test.
• Pregnant or lactating women.
• A heavy caffeine consumer(caffeine\>5 cups/day), alcohol consumer(alcohol\>210g/week), or smoker(cigarette\>10 cigarettes/day)
• Subject takes ethical drug or herbal medicine within 14 days, OTC(Over The Counter Drug) within 7 days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of subjects
• Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates etc.) within 30days.

Sponsors & Collaborators

• Chong Kun Dang Pharmaceutical: lead

Study Sites (1)

Severance Hospital

Seoul, Seodaemun-gu, 120-752, South Korea

Location

MeSH Terms

Conditions

Dyslipidemias

Interventions

CKD-519

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 7, 2015
• First Posted: June 29, 2015
• Study Start: June 1, 2015
• Primary Completion: August 1, 2015
• Study Completion: August 1, 2015
• Last Updated: December 7, 2015

Record last verified: 2015-12

Locations

KR (1)